-

BeiGene to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING--(BUSINESS WIRE)--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will participate in two upcoming investor conferences:

  • The 6th Annual Cowen IO Next Virtual Conference on Friday, November 11, at 9:40 a.m. (ET); and
  • The 13th Annual Jefferies Global Healthcare Conference in London on Wednesday, November 16 at 11:25 a.m. (ET).

A live webcast can be accessed from the investors section of BeiGene’s websites at https://ir.beigene.com, https://hkexir.beigene.com and https://sseir.beigene.com. An archived replay will be available for 90 days following the event.

About BeiGene
BeiGene is a global biotechnology company that is developing and commercializing innovative and affordable oncology medicines to improve treatment outcomes and access for far more patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of more than 9,000 colleagues spans five continents, with administrative offices in Beijing, China; Cambridge, U.S.; and Basel, Switzerland. To learn more about BeiGene, please visit www.beigene.com and follow us on Twitter at @BeiGeneGlobal.

Contacts

Investor
Kevin Mannix
+1-857-302-5189
ir@beigene.com

Media
Kyle Blankenship
+1 667-351-5176
media@beigene.com

BeiGene

NASDAQ:ONC
Details
Headquarters: San Carlos, CA & Basel, Switzerland, California
CEO: John V. Oyler
Employees: 11,000+
Organization: PUB
Revenues: $3.8B USD (2024)

Release Versions

Contacts

Investor
Kevin Mannix
+1-857-302-5189
ir@beigene.com

Media
Kyle Blankenship
+1 667-351-5176
media@beigene.com

More News From BeiGene

BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 2026

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from HERIZON-GEA-01 were published in The New England Journal of Medicine and will be presented in an oral presentation (Rapid Oral Abstract: 4010) at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2026, in Chicago. The HERIZON-GEA-01 clinical trial evaluated ZIIHERA® (zanidatamab) plus chemotherapy, with and without...

BeOne Medicines to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026, with a fireside chat at 10:00 a.m. EDT. The live webcast of this event can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com. An archived webcast will be available on the Company’s website. About BeOne BeOne Med...

BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that more than 60 abstracts across hematologic malignancies and solid tumors have been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago) and the 2026 European Hematology Association (EHA) Congress (June 11–14, Stockholm). Continuing to raise the bar in CLL At ASCO and EHA 2026, BeOne...
Back to Newsroom